CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical

CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC, E. coli NIHJ JC-2 pneumoniae E. coli 106, K. pneumoniae

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus

CHEMOTHERAPY 34 T-2588の APR.1986 嫌 気 性 菌 に 対す る抗 菌 作 用 に つ い て 沢 赫 代 神 野 英 毅 青 木 誠 小 林 と よ子 渡 辺 邦 友 上 野 一 恵 岐阜大学医学部附属嫌気性菌実験施設 新 し く 開 発 さ れ た 経 口 用 エ ス テ ル 型 セ フ ェ ム 系 抗 生 剤T-2588の 口 剤 で あ るcephalexin(CEX),cefaclor(CCL)

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

CHEMO THE RAPY OCT. 1994

bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri

CHEMOTHERAPY

CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT

JUNE 1988

JUNE 1988 VOL.36 S-2 CHEMOTHERAPY Table 1. Antibacterial activity of NY-198 against standard strains of bacteria By the agar-dilution method (inoculum: 106 CFU/ml) JUNE 1988 Fig. 3. Antibacterial activity

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, P. putrefaciens 279 A. faecalis 120, A. ordrans 114

988 CHEMOTHERAPY NOV. 1971

988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and

CHEMOTHERAPY JUNE 1986

VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml

VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

2 CHEMOTHERAPY JAN. 1976 VOL. 24 NO. 1 CHEMOTHERAPY 3 Table 1 Antibacterial spectra of Cephacetrile, Cephalothin, Cephaloridine and Cefazolin 4 CHEMOTHERAPY JAN. 1976 Fig. 1 In vitro activity of Cephacetrile,

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

Table1MIC of BAY o 9867 against standard strains

Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels

日本化学療法学会雑誌第61巻第6号

β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6- O-[3-deoxy-4 -C-methyl-3 -(methylamino) -ƒà-l- arabinopyranosyl]-2

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2

VOL. 28 S-2 CHEMOTHERAPY

VOL. 28 S-2 CHEMOTHERAPY CHEMOTHERAPY 52 (Oxaciliin hydrolysing Enterobacter cloacae P.mirabilis GN79, sp.gn69,お enzyme)の Nek E.ooli よ びE.coli た GN番 産 生 菌 と し て, 39, Proteus CSH vulgaris 2 (RK1), ML1410

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal

VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas

CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE

Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against

CHEMOTHERAPY Table 2 Clinical response of 6059-S by infection Table 3 Effect of 6059-S on blood chemistry *Normal range : S-GOT 20 `60 mu/ml, S-GPT 5 `25 IU/L, Al-Pase 30 `85 mu/ml In oilier cases : S-GOT

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic

Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table

Fig. 1 Chemical structure of KW-1070

Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized

Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.

VOL. 34 S-2 CHEMOTH8RAPY 913

VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

VOL. 20 NO. 5 CHEMOTHERAPY 653 2-Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3376, SDM, SIZ and SMZ against Gram-positive and negative

日本化学療法学会雑誌第64巻第4号

β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.

CHEMOTHERAPY APR. 1979

CHEMOTHERAPY APR. 1979 VOL.27 S-3 CHEMOTHERAPY CHEMOTHERAPY APR. 1070 Table 1 Comparison of antibiotic susceptibility of bacteria with the capacity to degrade cefotiam and other cephalosporine by /3-lactamase

CHEMOTHERAPY FEB Table 1 Background of volunteers

CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,

Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background

CHEMOTHERAPY SEPT. 1970

CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY 691 692 CHEMOTHERAPY SEPT. 1970 VOL. 78 NO. CHEMOTHERAPY 5 写 真1 第1病 693 写 真4 日 In vitroの しCEZの 第22病

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,

Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;

VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity

VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity CHEMOTHERAPY MAR. 1989 Mble 1. Allcrgy in parients nduced by penams VOL. 37 NO. 3 Table 2. Allergy in patients induced by

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination

Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar

56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit

VOL.27 S-1 CHEMOTHERAPY 55 56 CHEMOTHERAPY JAN. 1979 Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit VOL.27 CHEMOT S-1 Fig. 2 Effect of Mezlocillin on blood pressure (Sensitivity

180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab

June 2011 THE JAPANESE JOURNAL OF ANTIBIOTICS 64 23 179 ( 63 ) A b cefditoren pivoxil 5 amoxicillin 10 1,2) 1,3) 1) 1) 1) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 2011 4 8 2007 5 2009 4 A b GAS cefditoren pivoxil

VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of

VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of 4.9 g Mezlocillin Streptococcus pneumonzae pneumoniae

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1 VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

Pseudomonas aeruginosa S-827 Fig. 1. Method of biofilm formation. Table 1. Susceptibilities of antimicrobial agents on agar plate and in broth against Pseudomonas aeruginosa S-827 JULY CHEMOTHERAPY 888

VOL. 21 NO. 2 CHEMOTHERAPY 137

VOL. 21 NO. 2 CHEMOTHERAPY 137 Minimal inhibitory concentration (mcg/m1) of TM? and SMX in MUELLER-HINTON agar with 7.5% lysed horse blood, Diagnostic sensitivity test medium with 7. 596 lysed horse blood

VOL.42 S-1

CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum

日本化学療法学会雑誌第53巻第S-3号

moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium

Mueller-Hinton broth), Streptococcus pneumoniae (S. pneumoniae), Streptococcus faecalis (S. faecalis)

Fig. 1 Chemical structure of TA-058 (2S, 5R, 6R)-6- k2r-2- (2R-2- amino-3-n- methyl carbamoylpropionamido) -2- (4- hydroxyphenyl) acetamido l-3, 3-dimethy1-7-oxo- 4-thia-1- azabicycio k3.2,0 l heptane-2-carboxylic

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331

VOL. 36 S-3 CHEMOTHERAPY 437

VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,